Cabergoline in the treatment of hyperprolactinemia: A study in 455 patients

Journal of Clinical Endocrinology and Metabolism

Volumn 84, Issue 7, 1999, Pages 2518-2522

  Verhelst, Johan ^a   Abs, Roger ^b   Maiter, Dominique ^c   Van Den Bruel, Annick ^d   Vandeweghe, Mark ^e   Velkeniers, Brigitte ^g   Mockel, Jean ^f   Lamberigts, Gerard ^h   Petrossians, Patrick ⁱ   Coremans, Peter ^b   Mahler, Charles ^a   Stevenaert, Achille ⁱ   Verlooy, Jan ^b   Raftopoulos, Christian ^c   Beckers, Albert ⁱ  

^a MIDDELHEIM HOSPITAL   (Belgium)

^b ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^c CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^e GHENT UNIVERSITY HOSPITAL   (Belgium)

^f UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^g VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^h Sint Jan Ziekenhuis   (Belgium)

ⁱ UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; PROLACTIN; SOSTILAR;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HORMONE BLOOD LEVEL; HUMAN; HYPERPROLACTINEMIA; MAJOR CLINICAL STUDY; MALE; PREGNANCY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SYMPTOMATOLOGY; TREATMENT OUTCOME; TUMOR VOLUME; VISUAL FIELD DEFECT;

EID: 0033305762     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jcem.84.7.5810     Document Type: Article

References (23)

1. Dopaminergic treatments for hyperprolactinaemic disorders
2. Dopamine agonists and pituitary tumor shrinkage
3. Long-lasting prolactin-lowering effect of cabergoline, a new dopamine agonist, in hyperprolactinemic patients
4. For the cabergoline comparative study group. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea
5. Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline
6. Treatment of macroprolactinoma with cabergoline: A study of 85 patients
7. Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage
8. Cabergoline treatment rapidly improves gonadal function in hyperprolactinemic males: A comparison with bromocriptine
9. Cabergoline-treated hyperprolactinemia results in pregnancy in a bromocriptine-intolerant patient after seventeen years of infertility
10. Effects of the dopamine agonist cabergoline in patients with prolactinoma intolerant or resistant to bromocriptine
11. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment
12. The efficacy and tolerability of long-term cabergoline therapy in hyperprolactinaemic disorders: An open, uncontrolled, multicentre study
13. Use of cabergoline in the long-term treatment of hyperprolactinemic and acromegalic patients
14. Sex-related difference in the growth of prolactinomas: A clinical and proliferation marker study
15. Resistance to bromocriptine in prolactinomas
16. Cabergoline in the treatment of acromegaly: A study in 64 patients
17. Long-term treatment with cabergoline, a new long-lasting ergoline derivative, in idiopathic or tumourous hyperprolactinemia and outcome of drug-induced pregnancy
18. Pregnancy outcome after treatment with the ergot derivative, cabergoline
19. Cabergoline. A review of its pharmacologic properties and therapeutic potential in the treatment of hyperprolactinaemia and inhibition of lactation
20. Effectiveness and tolerability of long-term treatment with cabergoline, a new long-lasting ergoline derivative, in hyperprolactinemic patients
21. Cabergoline: Long-acting oral treatment of hyperprolactinemic disorders
22. Cabergoline in the long-term therapy of hyperprolactinemic disorders
23. Hyperprolactinemic amenorrhea: Treatment with cabergoline vs. bromocriptine. Results of a national multicenter randomized double-blind study